What we expect to see for aggressive lymphoma at the American Society of Hematology meeting in December is probably ...
Researchers have found the CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) to be a cost-effective second-line treatment for patients with relapsed and refractory diffuse large B-cell lymphoma ...
Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape. CS5001 is also being ...
Imugene ( ($AU:IMU) ) just unveiled an update. Imugene Limited has announced promising results from its Phase 1b clinical trial of azer-cel, an ...
A three-drug combination consisting of the antibody-drug conjugate brentuximab vedotin (Adcetris) plus lenalidomide (Revlimid) and rituximab for diffuse large B-cell lymphoma (DLBCL) improved survival ...
Refractory and relapsed DLBCL both present several treatment challenges, but available and upcoming options may help improve outcomes. Diffuse large B-cell lymphoma (DLBCL) is a subtype of non-Hodgkin ...
Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:ADCT), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with ...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on ...
NORTH CHICAGO, Ill., Sept. 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the feasibility of dosing and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback